AstraZeneca: towards a new indication for Lynparza


(CercleFinance.com) – The Committee for Medicinal Products for Human Use (CHMP) announced on Friday that it had adopted a favorable opinion with a view to marketing AstraZeneca’s Lynparza in a new indication.

This committee, which belongs to the European Medicines Agency (EMA), has issued a positive opinion on the marketing authorization application for the medicine in the treatment of metastatic castration-resistant prostate cancer in patients not eligible for chemotherapy.

Since the CHMP’s opinion is only advisory, the European Commission will have to make a final decision on this application for approval of the drug in the coming weeks. Brussels generally follows his advice.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85